FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer ...
Mayo

FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer ...

1080 × 1350 px October 16, 2025 Peter Mayo

FDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer ... is a high-quality image in the Mayo collection, available at 1080 × 1350 pixels resolution — ideal for both digital and print use.

Looking for a cost-effective alternative to heart failure medication? Explore our comprehensive guide on finding a generic for Entresto. Learn about sacubitril/valsartan availability, potential savings, therapeutic equivalence, and what you need to discuss with your cardiologist to manage your heart condition effectively while reducing prescription drug costs.

Image Details

TitleFDA’s first generic approvals slump 21% in 2024; Novartis’ top seller Entresto, cancer ...
Dimensions1080 × 1350 px
CategoryMayo
PublishedOctober 16, 2025
AuthorZeus
Downloads1,797
Views1,086

Read full article: Generic For Entresto

// More Images